Autophagy | Cholesterol biosynthesis promotes tumor immune escape by inhibiting MTOR-TFEB-mediated lysosomal degradation of PD-L1

This study reveals a direct link between intracellular cholesterol metabolism and anti-tumor immunity in cancer cells, providing a mechanistic basis for developing therapeutic strategies that combine targeting of HMGCR with immune checkpoint blockade. It holds significant implications for the field of tumor immunology.

 

Literature Overview

This paper, 'Tumorous cholesterol biosynthesis curtails anti-tumor immunity by preventing MTOR-TFEB-mediated lysosomal degradation of CD274/PD-L1,' published in the journal Autophagy, systematically investigates how cholesterol biosynthesis in tumor cells affects anti-tumor immunity by regulating the lysosomal degradation of CD274. By integrating bioinformatics analysis, in vitro co-culture systems, and mouse tumor models, the study uncovers a novel HMGCR-MTOR-TFEB-LAMP1 signaling axis that links cholesterol metabolism to immune checkpoint expression. Furthermore, it validates the pathway's predictive value for immunotherapy response and patient prognosis in clinical samples, offering new insights into the regulation of tumor immune metabolism.

Background Knowledge

Currently, tumor immune escape remains a core bottleneck limiting the efficacy of immunotherapy. Although PD-L1, a key immune checkpoint, has been extensively studied and known to be regulated at both transcriptional and post-translational levels, how its high expression is dynamically maintained in the tumor microenvironment remains incompletely understood. Cholesterol, a crucial component of cell membranes, exhibits abnormally activated biosynthesis in various cancers, yet whether and how it contributes to immune escape remains controversial. Previous studies have shown that SREBF-dependent cholesterol synthesis can enhance Treg cell function, while cholesterol levels in CD8+ T cells affect their activity, suggesting a complex role for cholesterol in immune regulation. However, whether tumor cell-intrinsic cholesterol biosynthesis directly impacts PD-L1 stability, particularly via the lysosomal pathway, has not been clearly elucidated. This study focuses on whether cholesterol biosynthesis influences CD274 protein degradation through TFEB-mediated lysosomal function, thereby enabling immune escape.

 

 

Research Methods and Experiments

The authors first performed gene set variation analysis (GSVA) using the TCGA database and found that the cholesterol synthesis pathway was negatively correlated with tumor-infiltrating lymphocytes (TILs), particularly significantly in SKCM (skin melanoma). Subsequently, immunohistochemical analysis of a tissue microarray containing 90 melanoma samples confirmed the negative correlation between HMGCR expression and CD8A and GZMB, suggesting that cholesterol synthesis suppresses T cell function. In vitro, simvastatin treatment of human melanoma cell lines (A2058, A375) co-cultured with activated T cells enhanced CD8+ T cell cytotoxicity, an effect dependent on CD274 downregulation. In the MC38 colon cancer mouse model, hmgcr knockout or pharmacological inhibition significantly enhanced the efficacy of anti-CTLA4 therapy, and CD8+ T cell depletion experiments confirmed the dependence of this effect on CD8+ T cells.

To elucidate the mechanism, the authors found that simvastatin did not alter CD274 mRNA levels but accelerated its protein degradation. Using MG132 and chloroquine to inhibit the proteasomal and lysosomal pathways respectively, they found that only chloroquine reversed PD-L1 degradation, indicating lysosomal dominance. Further investigation revealed that cholesterol depletion impaired MTOR activation on lysosomes, thereby inhibiting TFEB phosphorylation (Ser211), promoting its nuclear translocation, activating lysosomal biogenesis genes (such as LAMP1), and ultimately promoting PD-L1 degradation. Blocking lysosomal cholesterol efflux with U18666A reversed the inhibitory effect of simvastatin on MTOR-TFEB, confirming the critical role of cholesterol localization.

Key Conclusions and Perspectives

• Tumor cell cholesterol biosynthesis inhibits TFEB nuclear translocation by maintaining MTOR activity, thereby blocking lysosome-mediated CD274 degradation — this finding reveals a novel metabolism-lysosome-immunity axis, suggesting that targeting HMGCR could enhance immunogenicity and guide future combination therapy design
• High HMGCR expression correlates with poor response to anti-PD-1 therapy and adverse prognosis — this axis could serve as a potential biomarker to guide clinical stratification and advance precision immunotherapy strategies
• TFEB is the key transcription factor linking cholesterol metabolism to PD-L1 degradation — targeting TFEB nuclear translocation may represent a new direction for overcoming immune resistance, expanding our understanding of lysosomal regulation in tumor immunity
• MTOR activation on lysosomes depends on cholesterol accumulation — this provides a paradigm for how metabolites spatially regulate signal transduction, suggesting that subcellular metabolic microenvironments may determine signaling outcomes

Research Significance and Prospects

This study integrates cholesterol metabolism, lysosomal function, and immune checkpoint regulation, offering new target combinations for drug development, such as combining HMGCR inhibitors with PD-1/PD-L1 blockade. Additionally, the HMGCR-MTOR-LAMP1 expression profile could serve as a predictive biomarker to aid patient selection and improve immunotherapy response rates. The study also suggests a need to re-evaluate the use of statins in cancer patients, which may have potential immune-enhancing effects.

From a disease modeling perspective, generating genetically engineered mouse models that mimic abnormal cholesterol metabolism (e.g., tissue-specific hmgcr overexpression) would help validate the functional role of this pathway in vivo. Simultaneously, developing a reporter system to dynamically monitor lysosomal PD-L1 degradation could enable high-throughput screening of small molecules that promote PD-L1 degradation, opening new avenues for degrader-based drug discovery.

 

 

Conclusion

This study systematically elucidates the molecular mechanism by which tumor cells enhance cholesterol biosynthesis to inhibit the MTOR-TFEB signaling pathway, thereby blocking lysosomal degradation of PD-L1 and ultimately evading immune surveillance. This discovery not only reveals how metabolic reprogramming directly shapes an immunosuppressive microenvironment but also provides new strategies for clinical intervention. Targeting HMGCR can not only reduce tumor cell proliferation but also enhance CD8+ T cell activity and improve the efficacy of immune checkpoint blockade. Particularly in highly immunogenic tumors such as melanoma, the activation status of this pathway could serve as a predictive biomarker to guide personalized therapy. Future clinical trials combining statins with immunotherapy are warranted. Moreover, developing novel drugs that specifically promote lysosomal degradation of PD-L1 may become a key direction in overcoming immune resistance. This study provides a solid theoretical foundation and practical pathway for tumor immunotherapy, bridging basic mechanisms to clinical translation.

 

Huina Wang, Xiuli Yi, Di Qu, Weinan Guo, and Chunying Li. Tumorous cholesterol biosynthesis curtails anti-tumor immunity by preventing MTOR-TFEB-mediated lysosomal degradation of CD274/PD-L1. Autophagy.